Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013
Abstract
Introduction: Tuberculosis is a health problem worldwide. The World Health Organization estimated 9.6 million new cases and 480,000 multirresistant cases for 2014. The assessment of resistance to quinolones and injectables was implemented only a few years ago, so its prevalence is not known.
Objective: To determine the prevalence of resistance to amikacin, capreomycin and ofloxacin in cases of tuberculosis resistant to isoniazid and/or rifampin during 2012-2013.
Materials and methods: This was a cross-sectional study of 489 isolates resistant to isoniazid and/or rifampin. We used the Bactec MGITTM technique for susceptibility tests. For analyzing the rate of resistance, we grouped cases according to the history of treatment with second line drugs.
Results: In the 438 new cases, the drug that showed greater overall resistance was kanamycin with 7.1 % (95% CI: 4.6 to 9.6). In 51 previously treated cases, this highest resistance was 27.5 % (95% CI:14.2 to 40.7). The overall resistance was higher in cases with a history of treatment with quinolones and injectables. We found seven cases of extremely resistant tuberculosis.
Conclusion: This study demonstrates the presence of resistance to second line drugs in people with drug-resistant tuberculosis with and without previous treatment with quinolones and/or injectables, these latter having a higher percentage of resistance. For that reason, it is essential to perform susceptibility testing and analyze this information routinely.
Downloads
References
World Health Organization. What is DOT? A guide to understanding the WHO-recommended TB control strategy known as DOTS. Fecha de consulta: 28 de diciembre de 2015. Disponible en: http://apps.who.int/iris/handle/10665/65979
World Health Organization. Plan Mundial para Detener la Tuberculosis, 2006-2015. Ginebra: WHO 2006. Fecha de consulta: 28 de diciembre de 2015. Disponible en: http://apps.who.int/iris/handle/10665/43438
World Health Organization. Global tuberculosis control: Surveillance, planning, financing. Fecha de consulta: 28 de diciembre de 2015. Disponible en: http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=15&codcch=3659
World Health Organization. Global tuberculosis control WHO report – 2015. Fecha de consulta: 28 de diciembre de 2015. Disponible en: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1
Instituto Nacional de Salud. Informe final. Tuberculosis, Colombia - 2014. Fecha de consulta: 28 de diciembre de 2015. Disponible en: http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/Informe%20de%20Evento%20Epidemiolgico/Tuberculosis%202014.pdf
Instituto Nacional de Salud. Tuberculosis farmacorresistente. Nuevo evento de notificación obligatoria. Código 825 – 2013. Fecha de consulta: 28 de diciembre de 2015. Disponible en: http://www.ins.gov.co/Noticias/Memorias%20Reunin%20Nacional%20de%20Vigilancia%20y%20Control%20e/2-3-TB%20resistente.pdf
Clinical and Laboratory Standards Institute. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes. Approved standard. Second Edition. Wayne:CLSI: 2011.
Becton Dickinson. Inserto, técnica de MGIT 960® para evaluación de resistencia a fármacos antituberculosos. Heidelberg: Becton Dickinson; 2009.
Becton Dickinson. Manual Epicenter, técnica de MGIT 960® para evaluación de resistencia a fármacos antituberculosos. Heidelberg: Becton Dickinson; 2009.
Caminero J. Likelihood of generating MDR-TB and XDRTB under adequate national tuberculosis control programme implementation. Int J Tuberc Lung Dis. 2008;12:869-77.
Caminero J. Multidrug-resistant tuberculosis: Epidemiology, risk factor and case finding. Int J Tuberc Lung Dis. 2010;14:382-90.
Torres C, Awad C, Dennis R, Varón F. Lineamiento para el manejo programático de pacientes con tuberculosis farmacorresistente. Fecha de consulta: 28 de diciembre de 2015. Disponible en: http://www.ins.gov.co/lineasde-accion/Subdireccion-Vigilancia/micobacterias/Lineamientos%20manejo%20de%20Tuberculosis%20Farmacorresistente.pdf
Ministerio de Salud y Protección Social. Circular 001 del 8 de enero de 2013. Lineamientos para el manejo programático de los medicamentos de segunda línea para tuberculosis farmacorresistente en Colombia. Fecha de consulta: 28 de diciembre de 2015. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/circular-001-2013.pdf
Li N, Liao X, Chen L, Wang J, Liu M, Zhang H. Antibiotic susceptibility patterns of Mycobacterium tuberculosis isolates from Guizhou province of China against 13 antituberculosis drugs. Microb Drug Resist. 2015;21:292-6. http://dx.doi.org/10.1089/mdr.2014.0094
Nafees A, Arshad J, Syed A, Syed S, Long C, Izaz A, et al. Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients. Braz J Infect Dis. 2016;20:41-7. http://dx.doi.org/10.1016/j.bjid.2015.09.011
Jabeen K, Shakoor S, Malik F, Hasan R. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control. Int J Mycobacteriol. 2015;4(Suppl.1):47-8. http://dx.doi.org/10.1016/j.ijmyco.2014.10.046
Dalal A, Pawaskar A, DasM, Desai R, Prabhudesai P, Chhajed, et al. Resistance patterns among multidrugresistant tuberculosis patients in greater metropolitan Mumbai: Trends over time. PLoS One. 2015;10:e0116798. http://dx.doi.org.1371/journal.pone.0116798
Kempker R, Kipiani M, Mirtskhulava V, Tukvadze N, Magee M, Blumberg H. Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. Emerg Infect Dis. 2015;21:992-1001. http://dx.doi.org/10.3201/eid2106.141873
Asencios L, Quispe N, Mendoza A, Leo E, Vásquez L. Vigilancia nacional de la resistencia a medicamentos antituberculosos, Perú, 2005-2006. Rev Perú Med Exp Salud Pública. 2009;26:278-87.
Del Castillo H, Mendoza A, Saravia J, Somocurcio J. Epidemia de tuberculosis multidrogo resistente y extensivamente resistente a drogas (TB MDR/XDR) en el Perú: situación y propuestas para su control. Rev Perú Med Exp Salud Pública. 2009;26:380-6.
Barletta F, Zamudio C, Rigouts L, Seas C. Resistencia a drogas de segunda línea en cepas peruanas de Mycobacterium tuberculosis multidrogorresistentes. Rev Perú Med Exp Salud Pública. 2014;31:676-82.
Bastos M, Hussain H, Weyer K, García L, Leimane V, Leung CC, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to firstand second-line drugs: An individual patient data metaanalysis. Clin Infect Dis. 2014;59:1364-74. http://dx.doi.org/10.1093/cid/ciu619
Ho J, Jelfs P, Sintchenko V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis. 2014;26:149-53 http://dx.doi.org/10.1016/j.ijid.2014.03.1388
World Health Organization. The shorter MDR-TB regimen. Fecha de consulta: 14 de mayo de 2016. Disponible en: http://www.who.int/tb/Short_MDR_regimen_factsheet.
pdf?ua=1
World Health Organization. Tuberculosis diagnostics molecular line-probe assay for the detection of resistance to second-line anti-TB drugs (SL-LPA). Fecha de consulta: 14 de mayo de 2016]. Disponible en: http://www.who.int/tb/Factsheet_SLLPAfinal.pdf?ua=1
Álvarez D, Hernández S, Garza M, Vázquez R. Quinolonas. Perspectivas actuales y mecanismos de resistencia. Rev Chil Infectol. 2015;32:499-504. http://dx.doi.org/10.4067/S0716-10182015000600002
Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: Implications in settings with weak healthcare systems. Int J Infect Dis. 2015;32:118-23. http://dx.doi.org/10.1016/j.ijid.2015.01.006
Some similar items:
- Johana Rueda, Teresa Realpe, Gloria Mejía, Elsa Zapata, Jaime Robledo, GenoType MTBDRplus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis , Biomedica: Vol. 35 No. 4 (2015)
- Nelson José Alvis-Zakzuk, María de los Ángeles Carrasquilla, Verónica Jhajaira Gómez, Jaime Robledo, Nelson Rafael Alvis-Guzmán, José Mauricio Hernández, Diagnostic accuracy of three technologies for the diagnosis of multi-drug resistant tuberculosis , Biomedica: Vol. 37 No. 3 (2017)
- John-Leonardo Torres-Castiblanco, Jorge Alberto Carrillo, Daniel Hincapié-Urrego, Adriana Rojas-Villarraga, Tuberculosis in the era of anti-TNF-alpha therapy: Why does the risk still exist? , Biomedica: Vol. 38 No. 1 (2018)
- Claudia Llerena, Santiago Elías Fadul, María Consuelo Garzón, Graciela Mejía, Dora Leticia Orjuela, Luz Mary García, Hilda Beatriz Álvarez, Fernando Javier Ruiz, Drug-resistant Mycobacterium tuberculosis in children under 15 years , Biomedica: Vol. 30 No. 3 (2010)
- Dihadenys Lemus, Miguel Echemendía, Raúl Díaz, Alina Llop, María Josefa Llanes, Surveillance of antituberculosis-drug resistance in Cuba, 2010-2011 , Biomedica: Vol. 34 (2014): Abril, Suplemento 1, Resistencia bacteriana
- Leandro Galvis, Ángel Y. Sánchez, Leonardo F. Jurado, Martha I. Murcia, Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia , Biomedica: Vol. 38 No. 1 (2018)
- Angie Paola Zabaleta, Claudia Llerena, Angélica Valbuena, Resistant tuberculosis in children under 15 years of age, Colombia 2010-2015 , Biomedica: Vol. 39 No. 2 (2019)
- Claudia Llerena, Raquel Medina, Description of Mycobacterium tuberculosis mutations conferring resistance to rifampicin and isoniazid detected by GenoType® MTBDRplus V.2 in Colombia , Biomedica: Vol. 37 No. 1 (2017)
- Santiago Atehortúa, Faiver Ramírez, Lina María Echeverri, Adrian Peñata, Sigifredo Ospina, Xpert MTB/RIF test performance assay in respiratory samples at real work settings in a developing country , Biomedica: Vol. 35 No. 1 (2015)
- Juan Gabriel Bueno-Sánchez, Jairo René Martínez-Morales, Elena E. Stashenko, Wellman Ribón, Anti-tubercular activity of eleven aromatic and medicinal plants occurring in Colombia , Biomedica: Vol. 29 No. 1 (2009)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
